IRIS Accounts Production v25.4.0.155 09302382 Board of Directors 1.3.24 28.2.25 28.2.25 16.2.26 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 09302382 2024-02-29 09302382 2025-02-28 09302382 2024-03-01 2025-02-28 09302382 2023-02-28 09302382 2023-03-01 2024-02-29 09302382 2024-02-29 09302382 ns15:EnglandWales 2024-03-01 2025-02-28 09302382 ns14:PoundSterling 2024-03-01 2025-02-28 09302382 ns10:Director1 2024-03-01 2025-02-28 09302382 ns10:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 09302382 ns10:SmallEntities 2024-03-01 2025-02-28 09302382 ns10:Audited 2024-03-01 2025-02-28 09302382 ns10:SmallCompaniesRegimeForDirectorsReport 2024-03-01 2025-02-28 09302382 ns10:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 09302382 ns10:FullAccounts 2024-03-01 2025-02-28 09302382 ns10:OrdinaryShareClass1 2024-03-01 2025-02-28 09302382 ns10:Director2 2024-03-01 2025-02-28 09302382 ns10:CompanySecretary1 2024-03-01 2025-02-28 09302382 ns10:RegisteredOffice 2024-03-01 2025-02-28 09302382 ns5:CurrentFinancialInstruments 2025-02-28 09302382 ns5:CurrentFinancialInstruments 2024-02-29 09302382 ns5:ShareCapital 2025-02-28 09302382 ns5:ShareCapital 2024-02-29 09302382 ns5:RetainedEarningsAccumulatedLosses 2025-02-28 09302382 ns5:RetainedEarningsAccumulatedLosses 2024-02-29 09302382 ns5:LandBuildings 2024-02-29 09302382 ns5:PlantMachinery 2024-02-29 09302382 ns5:LandBuildings 2024-03-01 2025-02-28 09302382 ns5:PlantMachinery 2024-03-01 2025-02-28 09302382 ns5:LandBuildings 2025-02-28 09302382 ns5:PlantMachinery 2025-02-28 09302382 ns5:LandBuildings 2024-02-29 09302382 ns5:PlantMachinery 2024-02-29 09302382 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-02-28 09302382 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-02-29 09302382 ns10:OrdinaryShareClass1 2025-02-28 09302382 ns5:RetainedEarningsAccumulatedLosses 2024-02-29 09302382 ns5:RetainedEarningsAccumulatedLosses 2024-03-01 2025-02-28

REGISTERED NUMBER: 09302382 (England and Wales)

| Financial Statements |

| for the Year Ended 28 February 2025 |

| for |

| EPI-USE Labs Limited |

| EPI-USE Labs Limited (Registered number: 09302382) |

Contents of the Financial Statements

for the Year Ended 28 February 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| EPI-USE Labs Limited |

Company Information

for the Year Ended 28 February 2025

| DIRECTORS: | E Jones

| R J Patrick

| SECRETARY: | E Jones

| REGISTERED OFFICE: | Suite 11n-B, Trafford House Chester Road

| Stretford

| Manchester

| M32 0RS

| REGISTERED NUMBER: | 09302382 (England and Wales)

| SENIOR STATUTORY AUDITOR: | Ashfaq Sharif BA FCA CTA

| AUDITORS: | PB Associates

| Chartered Accountants and Chartered Tax Advisers

| 2 Castle Business Village

| Station Road

| Hampton

| Middlesex

| TW12 2BX

| EPI-USE Labs Limited (Registered number: 09302382) |

Balance Sheet

28 February 2025

| 28.2.25 | 29.2.24 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 113,373 |  | 65,118 |  |

CURRENT ASSETS

Debtors | 5 | 3,440,875 |  | 5,519,330 |  |

Cash at bank | 1,225,111 |  | 1,477,248 |  |

4,665,986 |  | 6,996,578 |  |

CREDITORS

Amounts falling due within one year | 6 | 2,568,831 |  | 4,874,657 |  |

NET CURRENT ASSETS | 2,097,155 |  | 2,121,921 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 2,210,528 |  | 2,187,039 |  |

PROVISIONS FOR LIABILITIES | 11,519 |  | 11,519 |  |

NET ASSETS | 2,199,009 |  | 2,175,520 |  |

CAPITAL AND RESERVES

Called up share capital | 7 | 100 |  | 100 |  |

Retained earnings | 8 | 2,198,909 |  | 2,175,420 |  |

SHAREHOLDERS' FUNDS | 2,199,009 |  | 2,175,520 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 February 2026 and were signed on its behalf by:

E Jones - Director

| EPI-USE Labs Limited (Registered number: 09302382) |

Notes to the Financial Statements

for the Year Ended 28 February 2025

1. | STATUTORY INFORMATION

| EPI-USE Labs Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention and are presented in sterling.

| Turnover

| Turnover represents net invoiced sales of goods and services, excluding value added tax, except in respect of service contracts where turnover is recognised upon completion.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| EPI-USE Labs Limited (Registered number: 09302382) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

2. | ACCOUNTING POLICIES - continued

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Tangible fixed assets

| Tangible fixed assets are depreciated at annual rates of 10% to 50% on cost.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 40 (2024 - 34 ) .

4. | TANGIBLE FIXED ASSETS

| Plant and |

| Land and |  | machinery |

| buildings |  | etc |  | Totals

£ | £ | £ |

| COST

| At 1 March 2024 | 10,563 |  | 245,884 |  | 256,447 |  |

| Additions | 22,177 |  | 74,072 |  | 96,249 |  |

| At 28 February 2025 | 32,740 |  | 319,956 |  | 352,696 |  |

| DEPRECIATION

| At 1 March 2024 | 1,686 |  | 189,643 |  | 191,329 |  |

| Charge for year | 9,682 |  | 38,312 |  | 47,994 |  |

| At 28 February 2025 | 11,368 |  | 227,955 |  | 239,323 |  |

| NET BOOK VALUE

| At 28 February 2025 | 21,372 |  | 92,001 |  | 113,373 |  |

| At 29 February 2024 | 8,877 |  | 56,241 |  | 65,118 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 28.2.25 |  | 29.2.24

£ | £ |

| Trade debtors | 2,910,201 |  | 5,018,523 |  |

| Amounts owed by group undertakings | 97,891 |  | 140,594 |  |

| Other debtors | 432,783 |  | 360,213 |  |

3,440,875 |  | 5,519,330 |  |

| EPI-USE Labs Limited (Registered number: 09302382) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 28.2.25 |  | 29.2.24

£ | £ |

| Trade creditors | 1,364,705 |  | 3,732,434 |  |

| Taxation and social security | 394,599 |  | 548,176 |  |

| Other creditors | 809,527 |  | 594,047 |  |

2,568,831 |  | 4,874,657 |  |

7. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 28.2.25 |  | 29.2.24

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

8. | RESERVES

| Retained

| earnings

£ |

| At 1 March 2024 | 2,175,420 |  |

| Profit for the year | 23,489 |  |

| At 28 February 2025 | 2,198,909 |  |

9. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Ashfaq Sharif BA FCA CTA (Senior Statutory Auditor)

| for and on behalf of PB Associates

| EPI-USE Labs Limited (Registered number: 09302382) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

10. | RELATED PARTY DISCLOSURES

| During the year the company made sales to group companies as follows:

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| EPI-USE Africa (Pty) Ltd |  |  | - |  | - |  |

| EPI-USE Labs GmbH |  |  | - |  | 89,027 |  |

| EPI-USE Labs Limited AE |  |  | 215,301 |  | 666,041 |  |

| EPI-USE Labs LLC |  |  | - |  | - |  |

| EPI-USE Labs Switzerland |  |  | 915,092 |  | 865,187 |  |

| EPI-USE Labs ZA |  | - |  | - |  |

| EPI-USE Limited |  |  | 283,402 |  | 282,913 |  |

| EULabs Limited |  |  | 402,659 |  | - |  |

| Group Elephant Limited (Previously EPI-USE Systems Limited) |  |  | - |  | 3,805 |  |

| G3G |  |  | 3,057 |  | - |  |

| During the year the company made purchases from group companies as follows:

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| EPI-USE Africa (Pty) Ltd |  |  | 89,920 |  | 71,642 |  |

| EPI-USE America |  |  | - |  | 194,837 |  |

| EPI-USE Cloud Services [AWS] |  |  | 46,980 |  | 37,123 |  |

| EPI-USE Labs GmbH |  |  | 485,442 |  | 187,074 |  |

| EPI-USE Labs LLC |  |  | 232,229 |  | 160,626 |  |

| EPI-USE Labs Switzerland |  |  | 2,582,729 |  | 2,335,664 |  |

| EPI-USE Labs ZA |  |  | 154,530 |  | 50,655 |  |

| EPI-USE Limited |  |  | 376,030 |  | 731,052 |  |

| EULabs Limited |  |  | 141,376 |  | 289,630 |  |

| Evolutio PS, LLC |  | - |  | - |  |

| G3G |  |  | 1,299,451 |  | 2,662,814 |  |

| At the balance sheet date the following amounts were due to group companies:

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| EPI-USE Africa (Pty) Ltd |  |  | -7,198 |  | -44,093 |  |

| EPI-USE America |  |  | -85,634 |  | -5,220 |  |

| EPI-USE Cloud Services [AWS] |  |  | -23 |  | -37,123 |  |

| EPI-USE Labs GmbH |  |  | -50,229 |  | -29,284 |  |

| EPI-USE Labs LLC |  |  | -6,200 |  | -6,356 |  |

| EPI-USE Labs Switzerland |  | -631,679 |  | -2,180,391 |  |

| EPI-USE Labs ZA |  | -5,320 |  | -4,866 |  |

| EPI-USE Labs Limited (Registered number: 09302382) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

| EPI-USE Limited |  |  | -208,890 |  | -464,282 |  |

| EULabs Limited |  |  | -30,463 |  | -30,463 |  |

| G3G |  |  | -203,831 |  | -659768 |  |

| At the balance sheet date the following amounts were due from group companies:

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| EPI-USE Labs GmbH |  |  | 4,568 |  | 5,312 |  |

| EPI-USE Labs Limited AE |  |  | 5,551 |  | 107,479 |  |

| EPI-USE Labs LLC |  |  | 69,709 |  | - |  |

| EPI-USE Labs Switzerland |  |  | 5,337 |  | 865,187 |  |

| EPI-USE Labs ZA |  |  | 4,758 |  | - |  |

| EPI-USE Limited |  |  | 31,792 |  | 145,629 |  |

| Group Elephant Limited |  |  | - |  | 10,890 |  |

| EPI USE LABS Denmark |  | 164,566 |  | - |  |

| EULabs BV |  |  | 441,415 |  | - |  |

11. | ULTIMATE CONTROLLING PARTY

| The controlling party is Group Elephant Limited, registered in the Isle of Man.

| There are a number of shareholders in Group Elephant Limited, none of whom hold a controlling interest in the company.